JOHNSON & JOHNSON Reports Second Quarter Earnings Results for FY2023

August 19, 2023

🌥️Earnings Overview

On July 31, 2023, JOHNSON & JOHNSON ($NYSE:JNJ) released their financial results for the second quarter of FY2023, which ended June 30, 2023. Their total revenue was reported at USD 25.5 billion, the same as the same quarter in the prior year. Net income was also equal to the same quarter in the prior year, coming in at USD 5.1 billion.

Share Price

The stock opened at $169.7 but closed at $167.5, a decrease of 4.0% from its previous closing price of 174.5. As a result, the company‚Äôs financial outlook for the rest of FY2023 is uncertain and they have been forced to re-evaluate their strategic direction. Despite these challenges, the company has remained committed to delivering quality products and services to its customers and providing value for its shareholders. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for JNJ. More…

    Total Revenues Net Income Net Margin
    97.77k 13.05k 12.5%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for JNJ. More…

    Operations Investing Financing
    23.42k -6.19k -18.02k
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for JNJ. More…

    Total Assets Total Liabilities Book Value Per Share
    179.23k 108.96k 27.04
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for JNJ are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    6.7% 6.9% 24.3%
    FCF Margin ROE ROA
    24.3% 21.1% 8.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we recently conducted an analysis of JOHNSON & JOHNSON’s wellbeing. Our Risk Rating found that JOHNSON & JOHNSON is considered a medium risk investment when it comes to both financial and business aspects. We also detected 2 risk warnings in the balance sheet, which were non-financial in nature. If you’d like to find out more about these warnings, please register on our website and explore further. We are always here to help you make informed decisions when it comes to investing. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition between Johnson & Johnson and its competitors is fierce. AstraZeneca PLC, Pfizer Inc, and BioNTech SE are all major players in the pharmaceutical industry, and they are all vying for a piece of the pie. Johnson & Johnson is a well-established company with a long history of success, but its competitors are not to be underestimated. They are all large, well-funded companies with a lot to lose if they don’t win the competition.

    – AstraZeneca PLC ($LSE:AZN)

    AstraZeneca PLC is a biopharmaceutical company with a market cap of 152.13B as of 2022. The company focuses on the discovery, development, and commercialization of small molecule drugs in the areas of oncology, cardiovascular, and renal & metabolism. The company’s ROE for the year ended December 31, 2020 was -0.94%.

    – Pfizer Inc ($NYSE:PFE)

    Pfizer Inc is a pharmaceutical company with a market cap of 240.55B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The company’s products include prescription and over-the-counter medicines, vaccines, and biologic therapies.

    – BioNTech SE ($NASDAQ:BNTX)

    BioNTech SE is a German biotech company founded in 2008 that focuses on the development of Innovation therapies against cancer and other serious diseases. The company has a market cap of 32.91B as of 2022 and a Return on Equity of 71.82%. BioNTech’s mission is to revolutionize the treatment of cancer and other serious diseases by leveraging the power of the immune system. The company is developing a portfolio of immunotherapy products based on its proprietary mRNA technology platform.


    Johnson & Johnson reported their quarterly financial results for Q2 2023 on July 31, 2023, with total revenue and net income staying flat year-over-year at $25.5 billion and $5.1 billion, respectively. Despite a strong financial performance, the stock price decreased on the news. This could indicate that investors have lowered expectations for future growth or are pricing in potential headwinds for the company. Investors should take a closer look at recent developments and analyze potential risks and opportunities before making any decisions on investing in Johnson & Johnson.

    Recent Posts

    Leave a Comment